ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy] by Year
Trajenta (linagliptin) — U.S. revenue ($M) [legacy] ($M)
Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy]: $82.1M in FY2021, down 14.1% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2021
82.1
Period ended Dec 31, 2021
Change on a year earlier
-14.1%
95.6 in FY2020
History
6 years
Since FY2016
Sources
4
Documents cited below
Where the FY2021 figure comes from
Source: Form 10-K (filed 2022-02-23) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trajenta (linagliptin) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 82.1 | -14.1% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 95.6 | -57.5% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 225 | +0.3% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 224 | +5.2% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 213 | +28.5% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 166 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy] ($M), annual FY2016–FY2021 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-trajenta-us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.